QIAGEN N.V.'s (QGEN) growth is backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to macroeconomic volatilities and currency fluctuations, which can adversely affect its financial results. Year to date, this Zacks Rank #3 (Buy) stock has risen 0.9% compared with 10.5% growth of the industry. The S&P 500 composite has witnessed an 18.1% rise in ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...

QIAGEN N.V.'s (QGEN) second-quarter 2024 adjusted earnings per share (EPS) were 55 cents, the same at the constant exchange rate (CER). The reported figure increased 7.8% from the 2023 comparable figure and topped the Zacks Consensus Estimate by 5.8%. The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others. On a GAAP basis, the lo ...

For the quarter ended June 2024, Qiagen (QGEN) reported revenue of $496.35 million, up 0.3% over the same period last year. EPS came in at $0.55, compared to $0.53 in the year-ago quarter. The reported revenue represents a surprise of +0.45% over the Zacks Consensus Estimate of $494.13 million. With the consensus EPS estimate being $0.52, the EPS surprise was +5.77%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.77%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.44 per share when it actually produced earnings of $0.46, delivering a surprise of 4.55%. Over the last four quarters, the ...

Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supportin ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Qiagen (QGEN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estima ...

QIAGEN N.V. (QGEN) is poised to grow in the upcoming quarters, backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. In addition, sound financial stability instills optimism. In the past year, this Zacks Rank #2 (Buy) stock has declined 10.4% compared with a 4% decrease in the industry. The S&P 500 composite has witnessed a 23.4% rise in the said time frame. Let's delve deeper. Progress in T ...

Qiagen (QGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Most Powerful Force Impacting Stock Prices As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where t ...

Core Insights - QIAGEN N.V. has announced a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance forensic applications and human identification using next-generation sequencing (NGS) technologies [1][2] - The partnership aims to provide forensic services for missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs) through advanced DNA technologies [3][6] Partnership Details - The collaboration will utilize QIAGEN's MiSeq FGx sequencing system, ForenSeq Kintelligence kits, and the ForenSeq Kintelligence HT System [1] - Snow Lab, in conjunction with Ohkomi Forensics, will establish the first indigenous-owned DNA database to identify remains of 95 African American individuals found in Sugar Land, TX [4][5] Technology and Market Potential - QIAGEN's NGS and forensic investigative genetic genealogy (FIGG) technologies can process severely degraded or contaminated DNA, which is common in forensic cases [6] - The global human identification market is projected to grow from $0.8 billion in 2024 to $1.3 billion by 2029, representing a compound annual growth rate (CAGR) of 10.7% [7] Recent Developments - In June 2024, QIAGEN launched 35 new digital PCR Microbial DNA Detection Assays for its QIAcuity platform, enhancing its microbial research capabilities [9] - QIAGEN's QIAstat-Dx Gastrointestinal Panel 2 received FDA clearance for clinical use, marking a significant advancement for the company in the U.S. market [10] Stock Performance - Over the past year, QIAGEN's shares have declined by 13.4%, compared to a 7.6% decline in the industry [11]